Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 108

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 108
---
 place of central management and control in United Kingdom, as determined by United Kingdom Panel
on Takeovers and Mergers, or the Takeover Panel. The Takeover Panel has confirmed we are subject to the City Code.

The City Code provides a framework
within which takeovers of certain companies organized in the United Kingdom are regulated and conducted. The following is a brief summary
of some of the most important rules of the City Code:

| • | In connection with a potential offer, if following an approach by or on behalf of a potential bidder,                                  
 the company is “the subject of rumor or speculation” or there is an “untoward movement” in the company’s                               
 share price, there is a requirement for the potential bidder to make a public announcement about a potential offer for the company, or 
 for the company to make a public announcement about its review of a potential offer.                                                   |

| • | When interests in shares carrying 10% or more of the voting rights of a class have been acquired by an                                    
 offeror (i.e., a bidder) in the offer period (i.e., before the shares subject to the offer have been acquired) or within the previous     
 12 months, the offer must be in cash or be accompanied by a cash alternative for all shareholders of that class at the highest price paid 
 by the offeror or any person acting in concert with them in that period. Further, if an offeror or any person acting in concert with them 
 acquires any interest in shares during the offer period, the offer for the shares must be in cash or accompanied by a cash alternative    
 at a price at least equal to the price paid for such shares during the offer period.                                                      |

| • | If after an announcement is made, the offeror or any person acting in concert with them acquires an interest                             
 in shares in an offeree company (i.e., a target) at a price higher than the value of the offer, the offer must be increased accordingly. |

| • | The board of directors of the offeree company must appoint a competent independent adviser whose advice                                
 on the financial terms of the offer must be made known to all the shareholders, together with the opinion of the board of directors of 
 the offeree company.                                                                                                                   |

| • | Favorable deals for selected shareholders are not permitted, except in certain circumstances where independent                        
 shareholder approval is given and the arrangements are regarded as fair and reasonable in the opinion of the financial adviser to the 
 offeree.                                                                                                                              |